Being tested
S1P receptor modulation (lymphocyte trafficking): protect nerve tissue in relapsing MS
relapsing MS · S1P receptor modulation (lymphocyte trafficking)
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 6
- Running now
- 2
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 6
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 6
These linked trials do not set the status.
Phase 4 · 2023 · Not randomised
- OMNIAOMSStopped, other reason
Phase 4 · 2023 · Not randomised
- DYNAMICS_StudyOngoing
Phase 4 · 2022 · Not randomised
- Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)Met main goal
Phase 4 · 2016 · Not randomised
- PASSOSNo result found
Phase 4 · 2012 · Not randomised
- DreaMSStopped: not working
Phase 2 · 2010 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Being tested
Related hypotheses
- S1P receptor modulation (lymphocyte trafficking): protect nerve tissue in optic neuritis
- S1P receptor modulation (lymphocyte trafficking): protect nerve tissue in primary progressive MS
- S1P receptor modulation (lymphocyte trafficking): protect nerve tissue in relapsing and progressive MS
- S1P receptor modulation (lymphocyte trafficking): protect nerve tissue in secondary progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error